On April 23, 2022, sponsored by the CSCO Expert Committee on Integrative Traditional Chinese and Western Medicine and undertaken by Hubei Mengyang Pharmaceutical Co., Ltd., the "Expert Consensus Tour on the Diagnosis and Treatment of Bone Myelosuppression Caused by Anti-tumor Drugs in Wuhan Station" was held in the cloud, attracting nearly 4,000 online views.

The conference was chaired by Professor Hua Haiqing from the General Hospital of the Eastern Theater of the People's Liberation Army and Professor Yuan Xianglin from Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology. Jiang Ziyu, Deputy Director of Jiangsu Provincial Hospital of Integrated Traditional Chinese and Western Medicine, Tian Shaodan, Director of Dongzhimen Hospital of Beijing University of Chinese Medicine, Liu Shuo, Director of Guang'anmen Hospital of China Academy of Chinese Medical Sciences, Cheng Yuan, Deputy Director of the General Hospital of the Eastern Theater of the People's Liberation Army, Professor Guo Yong of Zhejiang Provincial Hospital of Traditional Chinese Medicine, Professor Zhang Hongliang of Xinjiang Uygur Autonomous Region Hospital of Traditional Chinese Medicine, Director Zheng Zhi of Jiangxi Provincial People's Hospital and many other teaching experts and discussants reported and discussed the progress of diagnosis and treatment of related diseases with the theme of "Combination of Chinese and Western Medicine, Integrity and Innovation".

At the meeting, Jiang Ziyu, deputy director of Jiangsu Provincial Hospital of Integrated Traditional Chinese and Western Medicine, interpreted the "Expert Consensus on the Diagnosis and Treatment of Bone Marrow Suppression Caused by Anti-tumor Drugs" edited by the Special Committee. This paper expounds the drugs and risk factors that cause myelosuppression, the pathogenesis and pathogenesis of myelosuppression, the diagnosis and grading standards of traditional Chinese and Western medicine for myelosuppression, and the principles and programs of traditional Chinese and Western medicine treatment for myelosuppression. In the process of consensus interpretation, according to the ranking of evidence-based medical evidence, Director Jiang focused on the advantages of Shengbai oral liquid (mixture) widely used in myelosuppressive therapy.

In 2019, Shengbai Oral Liquid (Mixture) was included in the "Interpretation of TCM Diagnosis and Treatment Plans and Paths for Dominant Diseases of Blood Diseases", in order to develop expert advantages and organizational advantages, and promote the clinical value of TCM in the diagnosis and treatment of blood diseases, the conference specially invited Tian Shaodan, director of Dongzhimen Hospital of Beijing University of Chinese Medicine, to share the "Interpretation of TCM Diagnosis and Treatment Plans and Paths for Dominant Diseases of Blood Diseases" at the meeting. When talking about the syndrome differentiation and application of traditional Chinese medicine decoction in the treatment of leukopenia according to the degree of leukopenia and the patient's symptoms, it is proposed that among the marketed Chinese patent medicines, there are not many Chinese patent medicines with prescription correspondence, drug syndrome correspondence, and drug disease correspondence.

Then, Liu Shuo, director of Guang'anmen Hospital of China Academy of Chinese Medical Sciences, shared the progress of clinical research on "Shengbai Oral Liquid (Mixture)". Based on the results of modern pharmacological research, Director Liu gave a vivid and specific explanation of the mechanism of action of Shengbai oral liquid (mixture), and through the report of the results of preclinical research and post-marketing re-evaluation RCT studies, the experts at the meeting had a deep understanding of the effectiveness and safety of the product.

In the case sharing session, Cheng Yuan, deputy director of the General Hospital of the Eastern Theater of the People's Liberation Army, explained 6 typical effective cases of myelosuppression caused by chemotherapy caused by Shengbai oral liquid (mixture), and summarized that Shengbai oral liquid (mixture) has a clear effect on the prevention and treatment of bone marrow suppression after chemotherapy in cancer patients, and is safe to use.

Professor Guo Yong from Zhejiang Provincial Hospital of Traditional Chinese Medicine, Professor Zhang Hongliang from Xinjiang Uygur Autonomous Region Hospital of Traditional Chinese Medicine, and Director Zheng Zhi from Jiangxi Provincial People's Hospital jointly discussed the new ideas and methods of integrated traditional Chinese and Western medicine for the prevention and treatment of myelosuppression, and put forward expectations and prospects for the treatment of malignant tumor-related diseases with integrated traditional Chinese and Western medicine.

This expert consensus tour gathered many experts in the field of integrated traditional Chinese and Western medicine, creating a professional platform for academic exchanges and disciplinary discussions for medical colleagues. The successful conclusion of the first leg of the tour is just the beginning, Mengyang Pharmaceutical will continue to fully support the academic promotion work of the CSCO Expert Committee on Integrated Traditional Chinese and Western Medicine, and is committed to building a professional academic exchange platform, so as to further improve the standardization level of integrated traditional Chinese and Western medicine in the treatment of malignant tumors in China, reduce the incidence of toxic side effects in tumor-related treatments, improve the quality of life of patients, and ensure medical safety.